Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...

Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...

“Now, it means that we are not treating patients with therapies that should reduce and, in many cases, eliminate relapses,” she said, stressing that symptom change may not mean a relapse. “If a ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...